In today's Pharmalittle roundup, we're reading about HHS canceling a Moderna contract, FDA rejecting a rare disease drug, and ...

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...

Successful trial results in the next few years could save thousands of lives and generate billions in new annual revenue for ...

With a market cap of $681.8 billion, Eli Lilly and Company (LLY) is a leading global pharmaceutical company focused on ...

UnitedHealth Group (NYSE:UNH) has faced severe headwinds in 2025, with its stock plummeting over 50% from its April high.

The race to $1T is heating up. Based on current market capitalizations, the next wave of contenders ranges from just under ...

Earnings warnings, billion-dollar pivots, and vanishing guidance--how looming Trump-era tariffs could upend global business ...

Eli Lilly is making waves by acquiring SiteOne Therapeutics for up to $1 billion, eyeing a non-opioid chronic pain treatment.